Eosinophil as a cellular target of the ocular anti-allergic action of mapracorat, a novel selective glucocorticoid receptor agonist by Baiula, Monica et al.
Eosinophil as a cellular target of the ocular anti-allergic action of
mapracorat, a novel selective glucocorticoid receptor agonist
Monica Baiula,1 Antonino Spartà,1 Andrea Bedini,1 Gioia Carbonari,1 Claudio Bucolo,2 Keith W. Ward,3
Jin-Zhong Zhang,3 Paolo Govoni,4 Santi Spampinato1
1Department of Pharmacology, University of Bologna, Bologna, Italy; 2Department of Clinical and Molecular Medicine, University
of Catania, Catania, Italy; 3Pharmaceutical Research & Development, Bausch & Lomb, Rochester, NY; 4Department of
Experimental Medicine - Section of Histology, University of Parma, Parma, Italy
Purpose: Glucocorticoids can either suppress gene transcription (transrepression) or activate it (transactivation). This
latter process may contribute to certain side effects caused by these agents. Mapracorat (also known as BOL-303242-X
or ZK 245186) is a novel selective glucocorticoid receptor agonist that maintains a beneficial anti-inflammatory activity
but seems to be less effective in transactivation, resulting in a lower potential for side effects; it has been proposed for the
topical treatment of inflammatory skin disorders. This study assessed the anti-allergic activity of mapracorat at the ocular
level and whether eosinophils and mast cells are targets of its action.
Methods: With in vitro studies apoptosis was evaluated in human eosinophils by flow cytometry and western blot of
caspase-3 fragments. Eosinophil migration toward platelet-activating factor was evaluated by transwell assays. Interleukin
(IL)-6, IL-8, tumor necrosis factor-α (TNF-α), and the chemokine (C-C motif) ligand 5 (CCL5)/regulated upon activation
normal T cell expressed, and presumably secreted (RANTES) were measured using a high-throughput multiplex luminex
technology. Annexin I and the chemochine receptor C-X-C chemokine receptor 4 (CXCR4) were detected by flow
cytometry. With in vivo studies, allergic conjunctivitis was induced in guinea pigs sensitized to ovalbumin by an ocular
allergen challenge and evaluated by a clinical score. Conjunctival eosinophils were determined by microscopy or
eosinophil peroxidase assay.
Results: In cultured human eosinophils, mapracorat showed the same potency as dexamethasone but displayed higher
efficacy in increasing spontaneous apoptosis and in counteracting cytokine-sustained eosinophil survival. These effects
were prevented by the glucocorticoid receptor antagonist mifepristone. Mapracorat inhibited eosinophil migration and
IL-8 release from eosinophils or the release of IL-6, IL-8, CCL5/RANTES, and TNF-α from a human mast cell line with
equal potency as dexamethasone, whereas it was clearly less potent than this glucocorticoid in inducing annexin I and
CXCR4 expression on the human eosinophil surface; this was taken as a possible sign of glucocorticoid-dependent
transactivation. In the guinea pig, mapracorat or dexamethasone eye drops induced an analogous reduction in clinical
symptoms of allergic conjunctivitis and conjunctival eosinophil accumulation.
Conclusions: Mapracorat appears to be a promising candidate for the topical treatment of allergic eye disorders. It
maintains an anti-allergic profile similar to that of dexamethasone but seems to have fewer transactivation effects in
comparison to this classical glucocorticoid. Some of its cellular targets may contribute to eosinophil apoptosis and/or to
preventing their recruitment and activation and to inhibiting the release of cytokines and chemokines.
Allergic eye diseases are usually associated with type 1
hypersensitivity reactions, which cause early and late-phase
responses.  Clinical  symptoms  and  signs,  such  as  itching,
chemosis,  and  congestion,  driven  primarily  by  mast  cell
degranulation, are manifested very quickly. This is followed
by  the  late-phase  response  after  6–24  h,  which  involves
eosinophil  and  neutrophil  infiltration  into  the  conjunctiva
[1]. Inflammatory cells, cytokines, and proteases contribute
to more serious chronic forms [2].
Glucocorticoids are among the most effective drugs for
the treatment of allergic eye disease [3]. Their efficacy lies,
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among  other  things,  in  the  direct  induction  of  eosinophil
apoptosis,  suppression  of  the  synthesis  and  release  of
eosinophil  survival  factors,  and  stimulation  of  their
engulfment by phagocytic cells [4]. Unfortunately, their anti-
inflammatory and immunosuppressive effects are frequently
accompanied by undesired side effects that may limit their use
[5]. At the ocular level, classical glucocorticoids may cause
elevation of intraocular pressure and cataract formation [6].
There is, therefore, a pressing need for compounds with the
anti-inflammatory potency of standard glucocorticoids but
fewer or less troublesome side effects.
The most widely investigated effects of glucocorticoids
on  target  cells  involve  the  regulation  of  transcription  of
steroid-responsive genes as a consequence of their penetrating
the cytoplasm and binding to the glucocorticoid receptor; then
the glucocorticoid–glucocorticoid receptor complex reaches
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3208the  nucleus  and  acts  as  a  transcription  factor  binding  to
specific DNA sites in the nucleus. This can have two effects
on  gene  transcription:  it  can  either  activate  transcription
(transactivation) by directly binding to the promoter region of
target genes or by interacting with other transcription factors,
such as activator protein-1 (AP-1), nuclear factor κB (NF-
κB), and others, it can suppress transcription (transrepression)
[7]. The latter process is considered the key mechanism for
the anti-inflammatory activity [8,9]. However, there is also
evidence  that  glucocorticoid-mediated  repression  of
inflammatory genes involves significant post-transcriptional
and/or translational mechanisms [10], and the requirement for
de  novo  protein  synthesis  in  glucocorticoid-dependent
repression has been highlighted [11]. In contrast, certain side
effects  are  thought  to  be  mediated  mainly  through
transactivation [12].
A  better  understanding  of  the  molecular  mode  of
glucocorticoid action has led to the identification of novel
selective glucocorticoid receptor agonists that should preserve
the beneficial anti-inflammatory activity but offer a better
side-effect profile [13]. However, the utility of dissociated
glucocorticoid ligands as more effective anti-inflammatory
compounds with fewer side effects is still debated [11,14], and
studies aimed to investigate their pharmacological profile are
needed. In fact, so far the majority of these compounds did
not enter clinical development.
Recently,  Schäcke  et  al.  [15]  reported  the
pharmacological characterization of mapracorat (also known
as BOL-303242-X or ZK 245186), a nonsteroidal selective
glucocorticoid receptor agonist, for the topical treatment of
inflammatory  skin  disorders.  Mapracorat  binds  with  high
affinity and selectivity to the human glucocorticoid receptor,
possesses potent anti-inflammatory activity, but seems to be
less effective in transactivation, resulting in a lower potential
for side effects. Mapracorat topically administered as eye
drops  displays  a  reduced  ability  to  increase  intraocular
pressure  in  normotensive  rabbits  when  compared  to
dexamethasone [16] and behaves as a partial glucocorticoid
receptor agonist in inducing a moderate elevation of myocilin
expression in monkey trabecular meshwork cells [17]. Higher
levels  of  myocilin  have  been  related  to  glucocorticoid-
induced ocular hypertension and open-angle glaucoma [17];
however, a putative association between myocilin expression
and  open-angle  glaucoma  is  still  controversial  [18].
Conversely,  mapracorat  and  dexamethasone  were  equally
potent  in  blocking  inflammatory  cytokine  release  from
cultured human ocular cells [9] and modulating the mitogen-
activated  protein  kinases  and  nuclear  factor  kB  (NF-kB)
signaling cascades [19].
To date, the potential anti-allergic activity of mapracorat
in the eye and whether eosinophils and mast cells are targets
of  its  action  have  had  minimal  investigation.  This  study
specifically addressed these questions. Adopting in vitro and
in vivo models, we found that this novel compound appears
to behave as a “differential” glucocorticoid receptor agonist.
It  maintains  an  anti-allergic  profile  similar  to  that  of
dexamethasone  but  seems  to  have  fewer  transactivation
effects in comparison to this classical glucocorticoid. Schäcke
et  al.  [15]  reported  that  mapracorat,  unlike  classical
glucocorticoids,  does  not  induce  apoptosis  in  a  murine
thymocyte cell line; in contrast as regards human eosinophils,
we  have  ascertained  that  it  displays  higher  efficacy  than
dexamethasone  in  increasing  spontaneous  eosinophil
apoptosis—an  effect  related  to  its  anti-allergic  activity
observed in vivo.
METHODS
Reagents:  (R)-1,1,1-Trifluoro-4-(5-fluoro-2,3-
dihydrobenzofuran-7-yl)-4-methyl-2-{[(2-methyl-5-
quinolyl)amino]methyl}pentan-2-ol (mapracorat; molecular
weight 462.48) was provided by Bausch & Lomb (Rochester,
NY),  dexamethasone  21-phosphate  disodium  salt
(dexamethasone)  was  obtained  from  Sigma-Aldrich
(Steinheim, Germany), and mifepristone was purchased from
Tocris  Bioscience  (Bristol,  UK).  For  in  vitro  studies,
mapracorat, dexamethasone, and mifepristone were dissolved
in ethanol (10−2 M) and further diluted as necessary in cell
culture  medium.  The  vehicle  was  cell  culture  medium
containing 10 μl/ml of ethanol. For in vivo studies, mapracorat
eye drops were provided by Bausch & Lomb and further
diluted in phosphate buffered saline (PBS; 137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4 x 2 H2O, 1.76 mM KH2PO4,
pH 7.4); dexamethasone was dissolved in PBS.
Roswell  Park  Memorial  Institute-1640  (RPMI-1640)
plus L-glutamine, penicillin, streptomycin, Alexa Fluor® 488
and 568 conjugated secondary antibody, Hank’s balanced salt
solution (HBSS), and MagicMarkTM XP Western Standard
were  purchased  from  Invitrogen  (Carlsbad,  CA).  PBS,
Iscove’s modified Dulbecco’s medium, and heat inactivated
fetal bovine serum (FBS) were purchased from Lonza Group
Ltd. (Basel, Switzerland). Recombinant human granulocyte-
macrophage  colony-stimulating  factor  (GM-CSF)  was
obtained  from  R&D  Systems  (Minneapolis,  MN).
Interleukin-5 (IL-5), mouse monoclonal anti-chemokine (C-
X-C  motif)  receptor  4  (CXCR4)  antibody,  mouse  IgG1
(isotype  control),  ionomycin  from  Streptomyces
conglobatus, anti-β-actin antibody, BSA (BSA), ovalbumin
(OVA)  grade  V,  aluminum  hydroxide  gel,  o-
phenylenediamine, 30% hydrogen peroxide, Triton X-100,
and  peroxidase  acidic  isoenzyme  from  horseradish  were
obtained  from  Sigma-Aldrich.  Nuclear  and  Cytoplasmatic
Extraction Reagents kit, bicinchoninic acid (BCA) protein
assay,  and  SuperSignal  West  Pico  chemiluminescent
substrate were bought from Pierce (Rockford, IL). ProtranTM
was obtained from Whatman® (Kent, UK). Anti-caspase-3
antibody was purchased from Cell Signaling (Danvers, MA).
Mouse monoclonal anti-annexin I and peroxidase-conjugated
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3209secondary  antibodies  were  obtained  from  Santa  Cruz
Biotechnology  (Santa  Cruz,  CA).  Annexin  V-Fluos  was
obtained  from  Roche  Applied  Science  (Monza,  Italy).
Platelet-activating  factor  (PAF;  1-O-Octadecyl-2–0-acetyl-
sn-glycero-e-phosphoryl choline) was purchased from Sigma-
Aldrich and dissolved in ethanol (2 mM) and further diluted
in RPMI 1640 containing 0.1% BSA. Polyacrylamide gel,
N,N,N',N'-tetramethylethylenediamine,  ammonium
persulfate  hematoxylin-Bierbrich  scarlet  solution,  lithium
carbonate, and sodium dodecyl sulfate were purchased from
Sigma-Aldrich. All other reagents were of analytical grade or
the highest purity available, purchased from Sigma-Aldrich.
All plastic disposables were from Sarstedt (Verona, Italy).
Cell culture: Human eosinophils, isolated from whole blood
by density centrifugation followed by negative selection using
immunomagnetic anti-CD16 beads (purity and viability were
>95%), were purchased from 3H Biomedical AB (Uppsala,
Sweden) and routinely cultured in RPMI 1640 supplemented
with 10% FBS, antibiotics (100 U/ml penicillin and 100 μg/
ml  streptomycin),  GM-CSF  (70  pM),  and  IL-5  (30  pM).
Before each experiment, cells were maintained in RPMI 1640
medium containing 0.1% FBS and in the absence of GM-CSF
and IL-5.
A human mast cell line (HMC-1) [20], obtained from Pio
Conti  (University  of  Chieti,  Chieti,  Italy),  was  grown  in
Iscove’s modified Dulbecco’s medium containing 10% FBS,
100  U/ml  penicillin,  and  100  μg/ml  streptomycin  in  a
humidified atmosphere with 5% CO2 in air at 37 °C.
Animals: Male Dunkin-Hartley guinea pigs (250–300 g) were
purchased  from  Charles  River  (Calco,  Italy).  Animal
procedures  were  performed  in  accordance  with  the
Declaration  of  Helsinki,  followed  the  guidelines  of  the
University of Bologna Animal Care and Use Committee, and
were  comparable  to  those  published  by  the  Institute  for
Laboratory Animal Research.
Eosinophil cell apoptosis: To assess glucocorticoid-induced
apoptosis, cells were double stained with annexin V-Fluos and
propidium iodide (PI). Annexin V-Fluos was used according
to  the  manufacturer’s  instructions.  Briefly,  the  cells  were
washed in PBS and suspended in annexin V-Fluos labeling
solution (10 mM Hepes/NaOH, pH 7.4, 140 mM NaCl, 5 mM
CaCl2)  with  PI  added  (1  µg/ml).  The  suspension  was
incubated at room temperature for 10 min and analyzed in the
BD  FACS  Canto  II  flow  cytometry  system  (Becton,
Dickinson and Company, Franklin Lakes, NJ). Eosinophils
were gated on the basis of their forward and side light scatter,
with  cell  debris  excluded  from  analysis.  Cells  showing
positive staining with annexin V (i.e., both early apoptotic
annexin  V+/PI-  cells  and  late  apoptotic/secondary  necrotic
cells annexin V+/PI+) were considered to be apoptotic. A two-
way  dot  plot  was  prepared  to  verify  the  percentage  of
apoptotic cells. Annexin V-/PI- cells were used as control, and
annexin V-/PI+ cells were considered necrotic [21].
Flow cytometry: Fluorescence-activated cell sorting (FACS)
was performed to measure cell surface expression of annexin
I  and  CXCR4  as  indicators  of  glucocorticoid-mediated
transactivation [22]. Human eosinophils were double-stained
with  a  red  dye-conjugated  secondary  antibody  to  trace
changes in the expression of CXCR4 or annexin I and a green
dye-conjugated annexin V to exclude apoptotic cells from the
analysis. The cells were counted and transferred to a 24-well
plate (106 cells/well) and serum starved (0.1% FBS) for 24 h.
They were then exposed to dexamethasone or mapracorat for
24 h at 37 °C in 5% CO2 plus air.
At the end of the incubation, the cells were harvested and
each sample was divided into two tubes to run parallel tests
for annexin I and CXCR4 surface expression. After rinsing all
samples with an HBSS solution containing 1% BSA, the cells
were incubated for 45 min on a shaker with anti-annexin I or
anti-CXCR4 antibodies (1:200) on ice; the negative control
was incubated with an isotype-specific control antibody.
The cells were then washed twice with HBSS/BSA buffer
before  exposure  to  the  Alexa  Fluor®  568-conjugated
secondary antibody. The excess of unbound antibody was
washed away, and all samples were incubated for 15 min in
the presence of annexin V-Fluos. The cells were then rinsed
and resuspended in HBSS/BSA buffer and were ready for
analysis in the BD FACS Canto II flow cytometry system.
Electronic gates were set on annexin V-negative cells and
CXCR4 or annexin I-positive cells. Data from 10,000 cells/
sample  were  analyzed  using  dedicated  software  (Becton,
Dickinson  and  Company).  The  percentage  of  CXCR4  or
annexin I-positive cells was calculated [22].
Western blotting: Human eosinophils were centrifuged and
resuspended in 100 µl of Cytoplasmatic Extraction Reagent
(CER) I buffer (included in the Nuclear and Cytoplasmatic
Extraction Reagents kit). After 10 min incubation on ice,
5.5 µl of CER II buffer was added and the suspension was
resuspended by vortexing, incubated on ice for 1 min, and
resuspended.  The  cytoplasmic  fraction  was  separated  by
centrifugation at 16,000× g for 5 min. The protein content was
quantified using a BCA protein assay (Pierce). The proteins
of the cytoplasmic extract (50 µg) were denatured at 95 °C for
3 min, then loaded and separated by 15% sodium dodecyl
sulfate-PAGE.  MagicMarkTM  XP  Western  Standard  as  a
molecular weight standard was used.
Proteins  were  transferred  to  ProtranTM  nitrocellulose
membranes, which were blocked with 5% nonfat milk in Tris
buffered saline (10 mM Tris-HCl, pH 8, containing 150 mM
NaCl)  plus  0.1%  Tween-20  for  1  h  at  room  temperature
(25 °C). The blots were probed overnight at 4 °C in Tris
buffered saline containing 0.1% Tween-20, 5% nonfat milk,
and  antibodies  with  dilutions  of  1:1,000  for  caspase-3
monoclonal antibody or 1:5,000 for β-actin antibody (used as
a loading control for cytoplasmic cell lysates). The former
detects endogenous levels of procaspase-3 (around 32 kDa;
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3210p32) and its large subunit cleavage product of approximately
17  kDa  (p17)  [23].  The  membranes  were  incubated  with
peroxidase-conjugated secondary antibodies at a dilution of
1:8,000. Blots were finally developed with SuperSignal West
Pico chemiluminescent substrate for 5 min. The substrate was
prepared by mixing (1:1) the SuperSignal West Pico Stable
Peroxidase Solution and the SuperSignal West Pico Luminol/
Enhancer  Solution.  After  drainage  of  the  solutions,
chemiluminescence was acquired using a luminescent image
analyzer LAS-3000 (Fujifilm, Tokyo, Japan).
Eosinophil  migration  assay:  The  migration  of  human
eosinophils was assayed using TranswellTM inserts (pore size
5 μm) and 24-well culture plates (Corning Costar, Cambridge,
MA). Briefly, the cells (2×105) were suspended in 0.2 ml
RPMI-1640 medium containing 0.1% BSA, treated for 2 h
with  mapracorat  or  dexamethasone  (0.001–10  μM),  and
transferred to the upper compartment of the transwell insert.
PAF (200 μl of a 10−6 M solution) was added in the lower
compartment of the transwell insert. Vehicle-treated (control)
cells contained the same concentration of ethanol used to
dissolve  PAF  and  were  further  diluted  in  RPMI  1640
containing 0.1% BSA. After 2 h incubation in an atmosphere
of 95% air and 5% CO2, the number of cells that had migrated
from the upper to the lower compartment was counted using
a  hemocytometer.  The  calculated  half  maximal  inhibitory
concentration (IC50) indicates the concentration of mapracorat
or dexamethasone causing 50% inhibition of the maximal
number of cells that had migrated in comparison to control
cells.
Cytokine  and  chemokine  assays:  Human  eosinophils  or
HMC-1  cells  (5×105/ml)  were  suspended  in  RPMI  1640
containing  0.1%  FBS,  plated  onto  24-well  tissue  culture
plates, and pre-incubated in duplicate with dexamethasone or
mapracorat for 45 min before adding ionomycin (2 μM). After
18 h stimulation at 37 °C in a 5% CO2 atmosphere, IL-8 was
measured in supernatants obtained from eosinophils with a
commercial enzyme-linked immunosorbent assay (ELISA)
kit from R&D Systems. The threshold sensitivity was 5 pg/ml
and the inter- and intra-assay variations were less than 5%.
The supernatants obtained from HMC-1 cells were aliquoted
in duplicates for IL-6, IL-8, chemokine (C-C motif) ligand 5
(CCL5)/regulated upon activation, normal T-cell expressed
and secreted (RANTES), and tumor necrosis factor-α (TNF-
α)  analysis  using  high-throughput  multiplex  Luminex
technology  (Luminex  200  System;  Luminex,  Austin,  TX)
[9]  and  Beadview  software  version  1.0  (Upstate  Cell
Signaling  Solutions,  Temecula,  CA).  Standard  curves  for
known concentrations of recombinant human cytokines were
used to convert median fluorescence intensities to cytokine
concentrations  in  pg/ml.  Only  the  linear  portions  of  the
standard  curves  were  used  to  quantify  cytokine
concentrations,  and  in  instances  where  the  fluorescence
reading exceeded the linear range of the standard curve, an
appropriate  dilution  was  performed  to  ensure  that  the
concentration was in the linear portion of the curve.
The  calculated  IC50  indicates  the  concentration  of
mapracorat or dexamethasone causing 50% inhibition of the
maximal cytokine or chemokine release detected in control
cells.
Active anaphylaxis in the guinea pig: Male Dunkin-Hartley
guinea pigs were actively immunized by intraperitoneal (i.p.)
injection of 200 μg OVA in 2 ml saline with 40 mg aluminum
hydroxide (positive control) or saline alone (negative control)
[24]. This immunization procedure was repeated after one
week. Three weeks after the first immunization, mapracorat
and dexamethasone (0.4%, weight/volume) eye drops were
instilled into the conjunctival sac (30 µl/eye) of the treated
guinea pigs, and 45 min later the animals were challenged with
30 ml/eye of saline solution, containing 100 mg/ml OVA,
instilled into the conjunctival sac. Negative controls received
saline alone. Conjunctival clinical symptoms were rated blind
on both eyes using the following scale: 0, no symptoms; 1,
slight  conjunctival  redness  with  or  without  tears;  2,  mild
conjunctival redness with tears and mild chemosis; 3, mild
conjunctival redness with tears and moderate chemosis; 4,
severe conjunctival redness with tears and partial lid eversion;
5, severe conjunctival redness with tears and lids more than
half closed. The animals were euthanized 24 h after OVA
challenge by i.p. injection of Tanax® (3 ml/kg; Hoechst AG,
Frankfurt-am-Main,  Germany),  and  the  conjunctivas  were
carefully  excised  and  each  divided  into  two  samples  for
subsequent  investigations.  One  sample  was  fixed  in  10%
buffered paraformaldehyde solution and paraffin embedded;
slides, 6 μm thick, were stained with Luna’s eosinophil stain
to determine eosinophil accumulation and distribution. To
perform Luna’s eosinophil stain, slides were desiccated in
xylene, stained with hematoxylin-Biebrich scarlet solution,
differentiated in 1% acid alcohol, and subsequently stained
with lithium carbonate. Eosinophil granules stain red-orange
[25]. The number of eosinophils in each field was counted
under light microscopy (500× magnification). In the other
sample eosinophil peroxidase activity was measured.
Eosinophil  peroxidase  assay:  Eosinophil  peroxidase  was
assayed in conjunctival samples obtained as described above.
The tissues were washed twice with ice-cold PBS, weighed,
and homogenized with 50 mM Tris-HCl buffer (pH 8.0) using
a  Potter–Elvejehm  glass/teflon  homogenizer  (Wheaton,
Millville, NJ) on ice. After addition of 350 μl of 50 mM Tris-
HCl buffer and 150 μl of 0.1% Triton X-100, the homogenates
were placed in an ice bath for 1 h. The substrate solution
(400 μl of 50 mM Tris-HCl buffer containing 0.1% Triton
X-100, 1 mM o-phenylenediamine, and 0.5 mM hydrogen
peroxide) was added to 200 μl of the sample and incubated at
37 °C for 10 min. The reaction was stopped with 200 μl of 4
M  H2SO4.  Absorbance  was  measured  using  a
spectrophotometer (JASCO V-530, Jasco, Great Dunmow,
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3211Essex, UK) at 490 nm. A standard curve was plotted with
different concentrations of peroxidase diluted in 50 mM Tris-
HCl buffer (pH 6.0) containing 1 mM o-phenylenediamine
and  0.5  mM  hydrogen  peroxide.  Eosinophil  peroxidase
activity  was  measured  adopting  a  method  based  on  the
oxidation of o-phenylenediamine by eosinophil peroxidase in
the presence of hydrogen peroxide. One unit corresponds to 1
mmole of hydrogen peroxide decomposed for 10 min, and the
results were expressed as eosinophil peroxidase levels (mU of
enzyme/mg wet tissue) [24].
Data analysis: All data were expressed as mean±standard
error  of  the  mean  (SEM)  for  the  number  of  experiments
indicated. Statistical comparisons were made, as required, by
the Student t test, ANOVA, and post-hoc Newman–Keuls test
or two-way ANOVA with Bonferroni post test; differences of
p<0.05 were considered significant. For the clinical score,
each group comprised five animals. Nonparametric analysis
of the scores assigned to the conjunctival symptoms was done
using  the  Friedman  test  followed  by  Dunn's  post-hoc
comparison.  IC50  or  half  maximal  effective  concentration
(EC50)  values  and  associated  95%  confidence  limits  (CL)
correspond to the molar drug concentration producing 50% of
its  own  maximal  effect  and  were  generated  by  sigmoidal
nonlinear  curve  fitting  of  the  concentration-response  data
performed by Prism through a non-weighted iterative process
(Prism version 4.0, GraphPad Software, Inc., San Diego, CA).
RESULTS
Effect of mapracorat on spontaneous eosinophil apoptosis:
Peripheral human blood eosinophils cultured for up to 48 h
with 0.1% FBS and in the absence of prosurvival cytokines
showed time-dependent spontaneous apoptosis, determined
by flow cytometry to evaluate their ability to bind annexin V
and exclude PI (Figure 1). Exposure of eosinophils cultured
in 0.1% FBS and in the absence of prosurvival cytokines to
mapracorat or to the reference glucocorticoid dexamethasone
(0.001–10  μM)  for  48  h  enhanced  constitutive  eosinophil
apoptosis in a concentration-dependent manner. Mapracorat
was equally potent as dexamethasone but displayed a higher
efficacy. IC50 values were mapracorat 0.142 μM (95% CL
0.021–0.941 μM) and dexamethasone 0.142 μM (95% CL
0.023–0.884 μM). Mapracorat did not cause any significant
change of the concentration-response curve in comparison to
dexamethasone  (two-way  ANOVA  with  Bonferroni  post
test);  interestingly  it  showed  higher  efficacy  than
dexametasone  (mean±SEM  Emax=91±2.62  versus  78±2.23;
n=6; p<0.01; Student t test).
In eosinophils cultured with the vehicle, apoptosis was
similar to cells cultured in 0.1% FBS for 48 h (Figure 1A). In
eosinophils cultured in 0.1% FBS and exposed for 24 h to
mapracorat and dexamethasone (0.1, 1.0, and 10 μM), a lower
but  significant  apoptosis  was  observed  in  comparison  to
eosinophils cultured with the vehicle (data not shown).
Apoptosis induced by mapracorat was confirmed by the
characteristic  morphologic  features  on  light  microscopy
reported for glucocorticoids [23], such as cell shrinkage and
intense chromatin condensation (data not shown).
To confirm whether eosinophil apoptosis is induced by
mapracorat  through  the  glucocorticoid  receptor,  we
investigated the effect of mifepristone (10 μM) [26]. This
glucocorticoid  receptor  antagonist  prevented  apoptosis
induced by 5 and 10 μM mapracorat or dexamethasone in
human eosinophils (Figure 1).
To determine whether caspases were activated during
these processes, caspase-3 activation during mapracorat- or
dexamethasone-induced human eosinophil cell apoptosis was
investigated  by  western  blotting.  In  agreement  with  data
reported in Figure 1A, human eosinophils cultured for 24 h in
0.1% FBS and in the absence of prosurvival GM-CSF and
IL-5  constitutively  expressed  the  inactive  form  of
procaspase-3 (p32) and lower levels of its active subunit p17
(Figure  2).  There  was  a  marked  concentration-dependent
increase  of  the  p17  subunit  in  cells  exposed  for  24  h  to
mapracorat  or  dexamethasone  (0.001–10  μM;  Figure  2).
Increase of the p17subunit in cells exposed to mapracorat was
higher  than  that  observed  in  cells  exposed  to  the  same
concentration of dexamethasone (Figure 2). We detected no
changes in the amount of p32 and p17 in cells cultured for 24
h in the presence of the vehicle in comparison to control cells
cultured  for  24  h  in  0.1%  FBS  and  in  the  absence  of
prosurvival cytokines (control cells; Figure 2).
Effect  of  mapracorat  on  cytokine-sustained  eosinophil
survival:  Prosurvival  cytokines,  particularly  GM-CSF  and
IL-5, have been implicated in inhibiting eosinophil apoptosis,
while glucocorticoids have been reported to reverse cytokine-
sustained  cell  survival  [22,27].  As  previously  described,
human eosinophils cultured for 48 h in 0.1% FBS undergo
significant  apoptosis  determined  by  flow  cytometry  to
evaluate their ability to bind annexin V and exclude PI in
comparison to control cells routinely maintained in medium
containing 10% FBS (Figure 3). As expected, GM-CSF (70
pM) or IL-5 (30 pM) prevented eosinophil apoptosis. This
effect was reversed in a concentration-dependent manner by
dexamethasone or mapracorat (Figure 3A,B). Mapracorat was
equally as potent as dexamethasone; inhibition of GM-CSF-
induced  eosinophil  survival  results  were  mapracorat  IC50
0.154 μM (95% CL 0.079–0.301 μM) and dexamethasone
IC50 0.160 μM (95% CL 0.82–0.311 μM); mapracorat did not
cause any significant change in the concentration-response
curve in comparison to dexamethasone (two-way ANOVA
with  Bonferroni  post  test);  interestingly  it  showed  higher
efficacy than dexametasone (Emax=67±2.2 versus 47±2.1; n=6;
p<0.01). Inhibition of IL-5-induced eosinophil survival was
mapracorat IC50 0.156 μM (95% CL 0.073–0.335 μM) and
dexamethasone IC50 0.173 μM (95% CL 0.010–0.280 μM).
Mapracorat  did  not  cause  any  significant  change  in  the
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3212concentration-response  curve  in  comparison  to
dexamethasone  (two-way  ANOVA  with  Bonferroni  post
test), whereas it showed higher efficacy than dexametasone
(Emax=68±1.6  versus  51±2.3;  n=6;  p<0.01).  However,  this
effect is abolished when GM-CSF or IL-5 are used at higher
concentrations  [27].  Dexamethasone  and  mapracorat  were
not, in fact, able to reverse cytokine-sustained survival in the
presence  of  GM-CSF  200  pM  or  IL-5  100  pM  (data  not
shown).
Effect  of  mapracorat  on  eosinophil  migration  induced  by
platelet-activating factor: PAF (10−6 M) added in the lower
compartment  of  transwell  inserts  induced  a  significant
increase of eosinophil migration (mean±SEM 1,830±38 cells;
n=6) over controls (172±34 cells; n=6, p<0.01). Mapracorat
and dexamethasone (0.001–10 μM) caused a concentration-
dependent reduction of eosinophil migration from the upper
to the lower compartment of the transwell insert. Mapracorat
was equally as potent as dexamethasone; inhibition of PAF-
induced eosinophil migration results were mapracorat IC50
0.114 μM (95% CL 0.025–0.313 μM) and dexamethasone
IC50 0.148 μM (95% CL 0.035–0.402 μM); mapracorat did not
cause any significant change of the concentration-response
curve in comparison to dexamethasone (two-way ANOVA
with  Bonferroni  post  test);  interestingly  it  showed  higher
efficacy  than  dexamethasone  (Emax=93±4.0  versus  74±6.5;
n=6;  p<0.01).  Mifepristone  (10  μM)  co-incubated  with
mapracorat  or  dexamethasone  (5  or  10  μM)  prevented
eosinophil migration (data not shown).
Mapracorat  has  less  transactivation  activity  than
dexamethasone:  Activated  glucocorticoid  receptors  bind
recognition sites in the promoters of certain genes to activate
their  transcription;  this  is  known  as  transactivation.  The
CXCR4 receptor and annexin I can be considered markers of
glucocorticoid-induced  transactivation  [22].  To  determine
Figure  1.  Effects  of  mapracorat  and
dexamethasone  on  spontaneous
eosinophil  apoptosis.  A:  Peripheral
human blood eosinophils cultured up to
48 h in 0.1% fetal bovine serum (FBS)
and  in  the  absence  of  granulocyte-
macrophage  colony  stimulating  factor
and interleukin-5 show time-dependent
apoptosis.  Mapracorat  and
dexamethasone (0.001–10 μM) or their
vehicle were added for 48 h. Control
cells (Ctrl) were cultured in RPMI+10%
FBS.  Mifepristone  (10  μM)  was  co-
incubated  with  mapracorat  or
dexamethasone (5 or 10 μM). Apoptosis
was  determined  by  flow  cytometry,
evaluating  the  cell’s  ability  to  bind
annexin  V  and  exclude  propidium
iodide  as  described  under  Methods.
Results are expressed as percentages of
apoptotic cells. Data are presented as
mean±standard error of the mean from
six experiments performed in triplicate
using different eosinophil cell cultures.
*Versus  controls;  p  value  (p)<0.05.
**Versus  controls;  p<0.01.  #Versus
vehicle; p<0.01. ##Versus mapracorat or
dexamethasone  5  or  10  μM;  p<0.01.
§Versus  dexamethasone  at  the  same
concentration;  p<0.01.  B:  A
representative experiment showing total
percentage  of  apoptotic  eosinophils
(annexin  V+/propidium  iodide-  and
annexin  V+/propidium  iodide+  cells).
Abbreviations: Ctrl represents controls;
0.1 FBS represents 0.1% fetal bovine
serum;  MF  represents  mifepristone;
Dex  represents  dexamethasone;  Map
represents mapracorat.
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3213Figure 2. Mapracorat and dexamethasone induce caspase-3 activation in human eosinophils. Control cells were cultured for 24 h in 0.1% fetal
bovine serum and in the absence of granulocyte-macrophage colony stimulating factor and interleukin-5 and were treated with mapracorat or
dexamethasone (0.001–10 μM). Alternatively, eosinophils were exposed to the vehicle alone. A: A representative western blot, repeated at
least six times using different eosinophil cell cultures, with similar results, showing the bands of apparent molecular weights of caspase-3 of
approximately 32 kDa and 17 kDa and beta-actin of approximately 42 kDa. B: Densitometric analysis of the bands of caspase-3 fragment of
approximately 32 kDa. C: Densitometric analysis of the bands of caspase-3 fragment of approximately 17 kDa. The approximate molecular
mass of the fragments of 32 and 17 kDa was determined by comparison with molecular mass standards. The relative optical density of each
band was determined by densitometry and defined by normalization of the bands of capsase-3 32 kDa or 17 kDa to the β-actin band. A total
of 50 μg of protein extract was loaded and separated in a polyacrylamide gel, as described under “Methods..” Data are presented as mean
±standard, n=6. *Versus controls; p value (p)<0.05. **Versus controls; p<0.01. ***Versus controls; p<0.001. Abbreviations: Ctrl represents
controls; p32 represents apparent molecular weight of caspase-3 of approximately 32 kDa; p17 represents apparent molecular weight of
caspase-3 of approximately 17 kDa.
Molecular Vision 2011; 17:3208-3223 <http://www.molvis.org/molvis/v17/a346> © 2011 Molecular Vision
3214whether mapracorat maintains transactivation on binding to
the  glucocorticoid  receptor,  we  used  flow  cytometry  to
determine the induction of CXCR4 receptor and annexin I in
eosinophil cells exposed for 24 h to mapracorat (0.01–10 μM)
in comparison to the positive effect elicited by dexamethasone
(0.01–10 μM). As reported in Figure 4A, dexamethasone (1,
5, and 10 μM) induced a significant concentration-dependent
increase  of  the  CXCR4  receptor  expression;  conversely,
mapracorat  up  to  5  μM  did  not  change  CXCR4  receptor
expression  in  comparison  to  vehicle-treated  or  control
eosinophils. However, 10 μM mapracorat partially increased
this  receptor  on  the  cell  surface;  this  elevation  was
significantly lower than that induced by 1, 5, and 10 μM
dexamethasone. Results were similar for annexin I, which is
the other marker of glucocorticoid-induced transactivation
investigated  here  (Figure  4B).  These  data  indicate  that
Figure  3.  Effects  of  mapracorat  and
dexamethasone  on  cytokine-sustained
eosinophil survival. Control eosinophils
were routinely cultured in the presence
of 10% fetal bovine serum or for 48 h in
0.1%  fetal  bovine  serum  and  treated
with  granulocyte-macrophage  colony
stimulating  factor  (70  pM;  A)  or
interleukin-5  (30  pM;  B)  added
concomitantly  with  mapracorat  or
dexamethasone (0.001–10 μM) or their
vehicle. Apoptosis was determined by
flow  cytometry,  evaluating  the  cell’s
ability to bind annexin V and exclude
propidium  iodide  as  described  under
Methods.  Results  are  expressed  as
percentages of apoptotic cells. Data are
presented as mean±standard error of the
mean from six experiments performed
in triplicate using different eosinophil
cell  cultures.  **Versus  the  respective
control; p value (p)<0.01. ##Versus 0.1%
fetal  bovine  serum;  p<0.01  §§Versus
0.1%  fetal  bovine  serum+granulocyte
macrophage-colony  stimulating  factor
or  versus  0.1%  fetal  bovine  serum  +
interleukin-5;  p<0.01.  Abbreviations:
Ctrl represents controls; FBS represents
fetal bovine serum; GM-CSF represents
granulocyte-macrophage  colony
stimulating  factor;  IL-5  represents
interleukin-5.
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3215mapracorat is less potent than dexamethasone in activating
transactivation  mechanisms  regulated  by  glucocorticoid
agents.
The  upregulating  effect  of  1,  5,  and  10  μM
dexamethasone or 10 μM mapracorat on CXCR4 or annexin
I expression cannot be explained by its apoptosis-inducing
activity. Treated eosinophil cells were double stained with
annexin  V  and  anti-CXCR4  or  anti-annexin  I  and  their
expression  was  detected  in  cells  stained  negatively  with
annexin V.
Effect of mapracorat on cytokine secretion: Glucocorticoids
inhibit cytokine production and secretion in immune cells
[11]. This has been called transrepression and contributes to
their  anti-inflammatory  activity  [7,15].  In  view  of  the
substantial  apoptosis  caused  by  mapracorat  in  peripheral
blood eosinophils, we investigated its effect on IL-8 release
Figure  4.  Effects  of  mapracorat  and
dexamethasone on CXCR4 receptor and
annexin I surface expression in human
eosinophils. Eosinophils were routinely
cultured  in  10%  fetal  bovine  serum
containing  prosurvival  granulocyte-
macrophage  colony  stimulating  factor
and  interleukin-5  (controls);
alternatively,  eosinophils  were
maintained for 48 h in 0.1% fetal bovine
serum lacking granulocyte-macrophage
colony  stimulating  factor  and
interleukin-5  and  were  treated  with
mapracorat or dexamentasone (0.01–10
μM) or their vehicle. C-X-C-chemokine
receptor  4  (CXCR4)  or  annexin  1
expression  was  evaluated  by  flow
cytometry analysis as described under
Methods. CXCR4 receptor expression
(A) and annexin I expression (B) are
presented  as  percentages  of  positive
cells and calculated as described under
Methods. Data are presented as mean
±standard error of the mean from six
experiments  performed  in  triplicate
using different eosinophil cell cultures.
**Versus  vehicle;  p  (value)  p<0.01.
§Versus dexamethasone 1 μM; p<0.05.
§§Versus dexamethasone 5 and 10 μM;
p<0.01. Abbreviations: Ctrl represents
controls.
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3216from  ionomycin-treated  eosinophils.  IL-8  is  produced  by
eosinophils [28] and is involved in eosinophil migration and
survival, which are two relevant aspects in chronic allergic
diseases [29]. We also investigated the compound’s action on
cytokine and chemokine secretion in the human mast cell line
HMC-1 as these can greatly influence eosinophil activity in
inflamed ocular tissues [2].
Mapracorat  and  dexamethasone  (0.001–10  μM)  both
reduced IL-8 release induced by ionomycin in eosinophils
cells in a concentration-related manner (Figure 5). Mapracorat
displayed  potency  similar  to  dexamethasone  (mapracorat
IC50 0.020 μM, 95% CL 0.013– 0.132 μM; dexamethasone
IC50 0.064 μM, 95% CL 0.0037–0.109 μM) and did not cause
any significant change of the concentration-response curve in
comparison  to  dexamethasone  (two-way  ANOVA  with
Bonferroni post test). Similarly, both antagonized the release
induced  by  ionomycin  of  the  following  cytokines  from
HMC-1 cells: IL-6, IL-8, CCL5/RANTES, and TNF-α (IC50
results are reported in Table 1). Mapracorat was equally as
potent  as  dexamethasone  in  inhibiting  ionomycin-induced
secretion of IL-6, IL-8, CCL5/RANTES, and TNF-α.
Effect  of  mapracorat  on  conjunctival  symptoms  and
conjunctival eosinophil recruitment in ovalbumin-sensitized
guinea pigs: Guinea pigs were actively immunized by i.p.
injection of OVA and 2 weeks later were challenged with
OVA  instilled  into  the  conjunctival  sac.  One  hour  after
challenge, during the early phase ocular reaction, swelling of
the eyelids and chemosis were more marked in treated animals
than controls, but the difference was significantly reduced by
0.4% mapracorat or dexamethasone eye drops given before
treatment (30 µl/eye 45 min before OVA; Figure 6). During
the late phase of allergic conjunctivitis, 6 h after challenge,
there  was  still  a  significant  reduction  in  the  severity  of
conjunctival  symptoms  in  treated  guinea  pigs  with  both
compounds.
The  guinea  pigs  were  euthanized  by  intraperitoneal
injection of 3 ml/kg of Tanax® 24 h later and histological
analysis  showed  numerous  eosinophils  infiltrating  the
conjunctiva.  The  infiltration  was  much  less  marked  in
mapracorat- or dexamethasone-treated guinea pigs than in
OVA-treated animals (Figure 7A,B). Similarly, eosinophil
peroxidase  activity,  taken  as  an  indicator  of  eosinophil
infiltration, increased 24 h after antigen challenge in OVA-
treated guinea pigs, whereas there was a noteworthy reduction
in mapracorat or dexamethasone-treated animals (Figure 7C).
Figure 5. Effects of mapracorat and dexamethasone on interleukin-8 (IL-8) secretion induced by ionomycin in eosinophils. Cells (0.5x106
cells/well) were suspended in cell culture medium containing 0.1% fetal bovine serum and exposed to phosphate buffered saline (PBS) or to
the vehiche; alternatively, cells were treated with mapracorat or dexamethasone (0.001–10 μM); after 45 min, ionomycin (2 μM) was added.
Controls were not exposed to ionomycin. IL-8 was assayed by an enzyme-linked immunosorbent assay on supernatant samples collected 18
h later, as described under Methods. Data are presented as mean±standard error of the mean from six experiments performed in triplicate using
different eosinophil cell cultures (for the sake of clarity some error bars are not reported). Abbreviations: Ctrl, represents controls; ion represents
ionomycin; DEX represents dexamethasone. Mapracorat did not cause any significant change of the concentration-response curve in
comparison to dexamethasone (two-way ANOVA with Bonferroni post test).
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3217DISCUSSION
Schäcke et al. [15] recently described the pharmacological
profile  of  the  novel  dissociated  glucocorticoid  ligand
mapracorat, which was proposed for topical application to
treat skin disorders. This compound binds with high affinity
and selectivity to the human glucocorticoid receptor, inhibits
in vitro cytokine secretion from peripheral blood mononuclear
cells,  blocks  T-cell  proliferation  and,  when  topically
administered in vivo in two models of contact dermatitis, has
strong anti-inflammatory activity.
This study investigated the potential anti-allergic activity
of topical mapracorat in the eye and its effects in vitro on
eosinophil functions and cytokine secretion. We focused on
eosinophils since these cells mediate unique cytotoxic and
inflammatory effects by the generation, storage, and release
of their granule proteins and the production of cytokines,
growth  factors,  reactive  oxygen  species,  and  pro-
inflammatory  lipid  mediators  [4].  Their  recruitment  and
activation  are  regarded  as  crucial  to  the  development  of
allergic  disorders,  including  conjunctivitis  [1].  Besides
TABLE 1. INHIBITORY EFFECT OF MAPRACORAT AND DEXAMETHASONE ON THE RELEASE OF INTERLEUKIN-6, INTERLEUKIN-8, TNF-Α, AND CCL5/
RANTES INDUCED BY IONOMYCIN IN HUMAN HMC-1 CELLS.
Cytokine or chemokine assayed Mapracorat IC50 (µM) Dexamethasone IC50 (µM)
Interleukin-6 0.141  (0.053–0.320) 0.093 (0.045–0.165)
Interleukin-8 0.063 (0.039–0.164) 0.060 (0.025–0.117)
TNF-α 0.167 (0.041–0.182) 0.144 (0.056–0.298)
CCL5/RANTES 0.086 (0.044–0.398) 0.116 (0.061–0.597)
         The effect of mapracorat on secretion of the reported cytokines and chemokines, 18 h after ionomycin (2 μM) stimulation of
         HMC-1 cells, was determined in comparison to dexamenthasone. Compounds (0.001–10 μM) were added 45 min before
         ionomycin.  Values  were  calculated  by  analyzing  at  least  three  separated  experiments  performed  in  duplicate,  where
         concentration-response  curves  were  measured.  aFor  each  cytokine  or  chemokine  assayed,  mapracorat  did  not  cause  any
         significant  change of the concentration-response curve in comparison to dexamethasone (two-way ANOVA with Bonferroni
         post-test).                b 95% Confidence limits.
Figure  6.  Effects  of  mapracorat  and
dexamethasone  on  conjunctival
symptoms  induced  by  ovalbumin  in
guinea  pigs.  Mapracorat  and
dexamethasone  eye  drops  were
administered  to  guinea  pigs  actively
immunized  by  i.p.  injection  of
ovalbumin  (OVA)  and  2  weeks  later
challenged with OVA (30 µl of 2.5%
solution) instilled into both eyes; 45 min
before  this  challenge  mapracorat
(0.4%), dexamethasone (0.4%), or the
vehicle  (phosphate  buffered  saline)
were instilled into both eyes (30 µl/eye).
Controls received the vehicle alone and
were not treated with OVA. Each group
comprised  five  guinea  pigs,  and  the
score was based on changes before and
1,2, 4, and 6 h after challenge for the
symptoms of itching, swelling, redness,
and  lid  eversion  as  described  under
Methods. Data are presented as mean
±standard error of the mean, n=10 (both
eyes were evaluated). *Versus OVA or
OVA+vehicle;  p  (value)  p<0.05.
**Versus  OVA  or  OVA+vehicle;
p<0.01. Abbreviations: Ctrl represents
controls;  OVA  represents  ovalbumin;
DEX represents dexamethasone.
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a bFigure 7. Effects of mapracorat and dexamethasone eye drops on eosinophil infiltration induced by ovalbumin in the guinea pig conjunctiva
(details are reported in the legend of Figure 6). A: Photomicrographs of the conjunctiva 24 h after topical challenge with ovalbumin. Substantial
eosinophil infiltration is observed in ovalbumin-treated guinea pigs in comparison to negative controls treated with saline alone and not
challenged with ovalbumin. In guinea pigs treated with mapracorat or dexamethasone eye drops and 45 min later with ovalbumin, there was
much less eosinophil infiltration than in conjunctiva of guinea pigs treated with ovalbumin alone. B: Effects of mapracorat and dexamethasone
eye drops on conjunctival eosinophil infiltration 24 h after topical challenge with ovalbumin. The eosinophils in each field were counted 24
h after antigen exposure. Controls received saline alone and were not challenged with ovalbumin. C: Effects of mapracorat or dexamethasone
eye drops on conjunctival eosinophil peroxidase levels 24 h after topical challenge with ovalbumin. Controls received saline alone and were
not challenged with ovalbumin. **Versus ovalbumin; p value (p)<0.01. ##Versus controls; p<0.01. The original pictures were taken at 500x
magnification. The scale bar represents 50 μm. Abbreviations: CTRL represents controls; OVA represents ovalbumin; DEX represents
dexamethasone.
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3219selective  migration,  longer  cell  survival  and  decreased
apoptosis are relevant to tissue-specific accumulation of these
inflammatory cells [4].
Glucocorticoids are the most effective anti-inflammatory
drugs used to treat eosinophil disorders as they can prevent
eosinophil accumulation and activation and induce eosinophil
apoptosis [26,30,31]. We found that mapracorat, binding to
the glucocorticoid receptor, displayed potency similar to that
of  dexamethasone  and  was  more  effective  in  increasing
spontaneous  eosinophil  apoptosis  and  counteracting
cytokine-sustained  eosinophil  survival;  interestingly  the
difference between the two drugs is maintained when their
concentration reaches 10 μM. This was clear after 48 h of
treatment  in  peripheral  human  blood  eosinophils.
Furthermore,  we  proved  that  mapracorat  caused  a
concentration-dependent  inhibition  of  PAF-induced
eosinophil  migration.  Involvement  of  the  glucocorticoid
receptor was suggested by the effect of the glucocorticoid
receptor  antagonist  mifepristone  [26]  as  it  prevented
mapracorat-  or  dexamethasone-induced  apoptosis.  Taken
together, these results suggest that the inhibitory effect of
mapracorat on eosinophil accumulation observed in vivo at
the  conjunctival  level  may  involve  various  mechanisms,
including  eosinophil  apoptosis  and  their  recruitment  and
activation or release of cytokines and chemokines [32]. The
contribution  of  glucocorticoids  to  eosinophil  apoptosis  in
allergic diseases in vivo remains to be further investigated
[33].
Although  the  death  signal  that  triggers  the  apoptotic
program can originate from different sources, the signaling
pathways  ultimately  lead  to  the  activation  of  a  family  of
cysteine proteases known as caspases [34]. We showed that
mapracorat,  like  dexamethasone,  activates  caspase-3  by
interacting  with  the  glucocorticoid  receptor.  Its  apoptotic
effect on eosinophils might contribute in vivo to their rapid
removal by phagocytes to prevent their accumulation and the
release of cytotoxic proteins [31].
Schäcke  et  al.  [15]  reported  that  mapracorat,  unlike
classical glucocorticoids, does not induce apoptosis in the
murine thymocyte line S49. This difference calls for further
exploration  employing  human  thymocytes.  However,
according to Druilhe et al. [4] glucocorticoids may activate
different signaling pathways in these cells, and the marked
differences in the kinetics of glucocorticoid-induced death in
thymocytes (2–6 h) and eosinophils (24–48 h) must be borne
in mind.
Besides differences in species (human eosinophils versus
murine  thymocytes),  one  possible  explanation  of  the
mapracorat-induced eosinophil apoptosis is that its repressor
activity, which requires longer exposure, predominates in the
control of eosinophil apoptosis. This is borne out by present
data and previous studies [9,15] indicating that mapracorat has
a preference for repression mechanisms rather than activation
at a transcriptional level. This unique profile might be due to
its binding to the glucocorticoid receptor, which leads to a
change in receptor conformation. This could induce different
binding  with  other  co-factors  and/or  with  glucocorticoid
recognition elements residing in the promoter of target genes.
Helmberg et al. [35] suggested that interference with pro-
inflammatory signaling through transrepressional activity is
an important mechanism of glucocorticoid-induced apoptosis.
However, induction of the expression of pro-apoptotic agents
[31]  or  a  potential  effect  elicited  by  mapracorat  on
intracellular signaling involved in this process [36] cannot be
ruled out.
The  present  results  for  mapracorat  cannot  be  a
consequence of its degradation as Pfeffer et al. [17] have
shown that this compound is stable under conditions similar
to those adopted in the in vitro models used in the present
study.
We  confirmed  that  mapracorat  has  reduced
transactivation activity as it was partially effective only at the
highest concentration (10 μM) in inducing the expression of
the CXCR4 receptor and of annexin I on the eosinophil cell
surface. Conversely, the reference compound dexamethasone
was active at a concentration ten times lower (1 μM).
CXCR4  is  a  constitutive  chemokine  receptor  that  is
widely  expressed  on  leukocytes  and  enhances  the  active
retention of highly differentiated primed T cells at sites of
chronic inflammation [37]. These observations are interesting
because  in  vivo  studies  have  indicated  that  topical
glucocorticoids may potently upregulate CXCR4 expression
on primed T lymphocytes in the aqueous humor of patients
with uveitis [38]. In eosinophils, the expression of CXCR4 is
functional; a specific ligand for CXCR4, stromal cell-derived
factor 1α (SDF-1α), can elicit strong migration, comparable
with  that  of  eotaxin  [39].  Therefore,  the  finding  that
mapracorat  is  a  weaker  activator  than  dexamethasone  of
CXCR4 expression in eosinophils could be favorable for anti-
allergic activity. However, in vivo evidence of the role of
glucocorticoids in CXCR4 expression in eosinophils is still
lacking, and further investigations are necessary to clarify this
receptor’s intriguing role in eosinophil recruitment.
As  regards  the  reduced  transactivational  activity  of
mapracorat-induced  annexin  I  expression,  this  might
negatively influence its anti-allergic properties [40]. Annexin
I on the eosinophil surface is upregulated by glucocorticoids
and  prevents  integrin  adhesion,  which  is  essential  to  cell
migration [41]. Again, in vivo studies aimed to evaluate the
effect  of  mapracorat  on  annexin  I  expression  are  needed.
However, this effect does not affect the anti-allergic activity
of mapracorat as we found it had potent anti-allergic activity
in OVA-sensitized guinea pigs. Furthermore, a recent study
has reported that mapracorat acts as a partial glucocorticoid
receptor  agonist  in  increasing  a  moderate  elevation  of
myocilin expression in trabecular meshwork cells—an effect
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3220that may be due to its peculiar regulation of transactivation
mechanisms [17].
Gene repression modulated by mapracorat can contribute
indirectly  to  eosinophil  apoptosis  and/or  activation  by
inhibiting cytokine and chemokine production and secretion
by the eosinophils and mast cells [42]. This agent caused
concentration-related  inhibition  of  IL-8  release  from
eosinophils and the release of IL-6, IL-8, CCL5/RANTES,
and TNF-α from HMC-1 human mast cells. In agreement with
our  findings,  Zhang  et  al.  [9]  and  Cavet  et  al.  [19]  have
reported that mapracorat may act, at an ocular level, as a potent
anti-inflammatory agent as it blocks the release of various
cytokines and chemokines in various primary human ocular
cells with similar activity and potency as dexamethasone.
These effects help to explain the potent anti-allergic effect of
mapracorat  in  reducing  the  conjunctival  symptoms  and
conjunctival  eosinophil  accumulation  in  OVA-sensitized
guinea pigs.
This novel compound behaves as the full glucocorticoid
receptor agonist dexamethasone and has beneficial effects on
early and late-phase inflammatory changes induced by the
allergen-specific  conjunctival  challenge.  Histamine  and
eicosanoids  are  responsible  for  the  typical  early  phase
response  [3].  However,  mast  cells  also  contribute  to  the
synthesis and release of cytokines, chemokines, and growth
factors, triggering a cascade of inflammatory events on the
surface of epithelial and endothelial cells that leads to the late-
phase  response,  with  recruitment  of  eosinophils  and
neutrophils [3]. Therefore mapracorat, as suggested by Zhang
et al. [9] and Cavet et al. [19], may act on different cell types
involved in the complex inflammatory response in the eye by
influencing the production of pro-inflammatory cytokines and
chemokines as well as inducing eosinophil apoptosis. These
effects  appear  to  be  predominantly  regulated  by  the
transrepressional arm of glucocorticoid action [7].
In  terms  of  separating  transactivation  from
transrepression, it is clear that many genes regulated through
transactivation are not represented in current screening assays.
Thus,  the  dissociation  actually  shown  by  these  novel
compounds  obviously  needs  further  investigation  [8,14].
Several  glucocorticoid-inducible  genes  contribute  to  their
anti-inflammatory action, and the loss of any transactivational
properties might reduce this [11]. Therefore, it is essential to
verify  the  anti-inflammatory  activity  of  these  novel
glucocorticoid receptor ligands in vivo in models where both
favorable and unfavorable transactivation and transrepression
events occur. Finally, as reported by Newton and Holden
[14], it would be better to search for “differential” compounds
that show the most favorable functional profiles rather than
searching  for  glucocorticoid  ligands  that  distinguish
transrepression and transactivation.
In  conclusion,  mapracorat  seems  to  be  a  promising
candidate for the topical treatment of allergic eye disorders. It
easily appears to reach conjunctival cells and vessels when
administered topically [43], and some of its cellular targets
may contribute to eosinophil apoptosis and/or to preventing
their recruitment and activation and to inhibiting the release
of cytokines and chemokines. Future studies should further
explore  its  safety  profile  and  better  define  its
pharmacodynamic profile.
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